Apotheken
|
Doctor
|
Drugs
|
Hospital
|
Interactions
|
MiGeL
|
Registration owner
|
Services
Recent Registrations
Price comparison
Price comparison and Component
Brand name
Component
Registration owner
Indication
Interaction
Unwanted Effect
Swissmedic-# (5-digit)
Pharmacode
Product
Package Size
EFP
CP
SB
DC
Composition
Registr. Holder
Category
January
-
February
- March - April - May - June - July - August - September - Oktober - November - December |
2002
-
2003
-
2004
-
2005
-
2006
-
2007
-
2008
-
2009
-
2010
-
2011
-
2012
-
2013
-
2014
-
2015
-
2016
-
2017
-
2018
-
2019
-
2020
-
2021
-
2022
-
2023
-
2024
- 2025
March 2025 - 52 products
A
Digestodoron N
50 ml
PR
PR
k.A.
Weleda AG
D
FB
G
Relfydess 150 units/ 1,5 ml
PR
PR
k.A.
Injection solution: Toxinum Botulinicum a (Stirpis I01) 150U. / 1.5ml
Ipsen Pharma Schweiz
GmbH
A
FB
G
Relfydess 150 units/ 1,5 ml
10
PR
PR
k.A.
Injection solution: Toxinum Botulinicum a (Stirpis I01) 150U. / 1.5ml
Ipsen Pharma Schweiz
GmbH
A
FB
G
Testosteroni undecanoas SIT
1000 mg
PR
PR
k.A.
Injection solution: Testosteroni Undecanoas
Laboratorio
Farmaceutico S.I.T. -
Specialità igienico
terapeutiche S.r.l.,
Mede, succursale di
Chiasso
B
FB
G
IP
Xbryk 120 mg/1.7 ml
PR
PR
k.A.
Injection solution: Denosumabum 120mg / 1.7ml
Samsung Bioepis CH
GmbH
A
FB
G
Enbrel 25 mg
4
PR
PR
k.A.
Injection solution in prefilled syringe: Etanerceptum 25 mg/ml
Pharma Nova GmbH
B
FB
G
IP
Obodence
PR
PR
k.A.
Injection solution in prefilled syringe: Denosumabum 60 mg/ml
Samsung Bioepis CH
GmbH
B
FB
G
IP
Pyzchiva 45 mg/0.5 mL
PR
PR
k.A.
Injection solution in prefilled syringe: Ustekinumabum 45mg / 0.5ml
Samsung Bioepis CH
GmbH
B
FB
G
IP
Pyzchiva 90 mg/1 mL
PR
PR
k.A.
Injection solution in prefilled syringe: Ustekinumabum 90 mg/ml
Samsung Bioepis CH
GmbH
B
FB
G
Sildenafil Direct Mint
Spirig HC 25 mg
4
PR
PR
k.A.
Chewing tablets: Sildenafilum 25 mg
Spirig HealthCare AG
B
FB
G
Sildenafil Direct Mint
Spirig HC 50 mg
4
PR
PR
k.A.
Chewing tablets: Sildenafilum 50 mg
Spirig HealthCare AG
B
FB
G
Sildenafil Direct Mint
Spirig HC 100 mg
4
PR
PR
k.A.
Chewing tablets: Sildenafilum 100 mg
Spirig HealthCare AG
B
FB
G
IP
CI
Bilastin-Mepha Allergie
lingual 20 mg
10
PR
PR
k.A.
Melting tablets: Bilastinum 20 mg
Mepha Pharma AG
D
FB
G
IP
CI
Bilastin-Mepha Allergie
lingual 20 mg
30
PR
PR
k.A.
Melting tablets: Bilastinum 20 mg
Mepha Pharma AG
D
FB
G
IP
CI
Bilastin-Mepha Allergie
lingual 20 mg
50
PR
PR
k.A.
Melting tablets: Bilastinum 20 mg
Mepha Pharma AG
D
FB
G
Bexin Hustenstiller
Butamirat
200 ml
PR
PR
k.A.
Sirup: Butamirati Dihydrogenocitras 1.5 mg/ml/ml
Spirig HealthCare AG
D
FB
G
IP
ELAHERE 100 mg/20 ml
PR
PR
k.A.
Concentrate for infusion: Mirvetuximabum Soravtansinum 100mg / 20ml
AbbVie AG
A
FB
G
IP
Pyzchiva 130 mg
PR
PR
k.A.
Concentrate for infusion: Ustekinumabum 130mg / 26ml
Samsung Bioepis CH
GmbH
B
FB
G
Triamcinolon LEMAN
PR
PR
k.A.
Nasal spray: Triamcinoloni Acetonidum
Leman SKL SA
B
FB
G
Diosmin axapharm 1000 mg
30
PR
PR
k.A.
Coated tablets: Diosminum 1000 mg
axapharm ag
D
FB
G
Enzalutamid Spirig HC 40 mg
112
PR
PR
k.A.
Coated tablets: Enzalutamidum 40 mg
Spirig HealthCare AG
B
FB
G
Enzalutamid Spirig HC 80 mg
56
PR
PR
k.A.
Coated tablets: Enzalutamidum 80 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC 250 mg
30
PR
PR
k.A.
Coated tablets: Levetiracetamum 250 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC 500 mg
20
PR
PR
k.A.
Coated tablets: Levetiracetamum 500 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC 500 mg
100
PR
PR
k.A.
Coated tablets: Levetiracetamum 500 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC 500 mg
200
PR
PR
k.A.
Coated tablets: Levetiracetamum 500 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC
1000 mg
30
PR
PR
k.A.
Coated tablets: Levetiracetamum 1000 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC
1000 mg
100
PR
PR
k.A.
Coated tablets: Levetiracetamum 1000 mg
Spirig HealthCare AG
B
FB
G
IP
Levetiracetam Spirig HC
1000 mg
200
PR
PR
k.A.
Coated tablets: Levetiracetamum 1000 mg
Spirig HealthCare AG
B
FB
G
VANFLYTA 17.7 mg
14
PR
PR
k.A.
Coated tablets: Quizartinibi Dihydrochloridum 20 mg
Daiichi Sankyo
(Schweiz) AG
A
FB
G
VANFLYTA 17.7 mg
28
PR
PR
k.A.
Coated tablets: Quizartinibi Dihydrochloridum 20 mg
Daiichi Sankyo
(Schweiz) AG
A
FB
G
VANFLYTA 26.5 mg
14
PR
PR
k.A.
Coated tablets: Quizartinibi Dihydrochloridum 30 mg
Daiichi Sankyo
(Schweiz) AG
A
FB
G
VANFLYTA 26.5 mg
28
PR
PR
k.A.
Coated tablets: Quizartinibi Dihydrochloridum 30 mg
Daiichi Sankyo
(Schweiz) AG
A
FB
G
VANFLYTA 26.5 mg
56
PR
PR
k.A.
Coated tablets: Quizartinibi Dihydrochloridum 30 mg
Daiichi Sankyo
(Schweiz) AG
A
FB
G
Jakavi 5 mg/ml
60 ml
PR
PR
k.A.
Solution (oral): Ruxolitinibum 5 mg/ml
Novartis Pharma
Schweiz AG
A
FB
G
PneumoXON 0,25% / 10%
10 l
PR
PR
k.A.
Gas zur medizinischen Anwendung: 2 Active Agents
Messer Schweiz AG
A
FB
G
PulmoProDiff 0,25% / 18%
10 l
PR
PR
k.A.
Gas zur medizinischen Anwendung: 2 Active Agents
Messer Schweiz AG
A
FB
G
Remsima 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
Pharma Nova GmbH
A
FB
G
Remsima
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
Pharma Nova GmbH
A
FB
G
Remsima 100 mg
PR
PR
k.A.
Pulver für ein Konzentrat zur Herstellung einer Infusionslösung: Infliximabum 100 mg
Pharma Nova GmbH
A
FB
G
Latazed 50 ug/ml
2.5 ml
PR
PR
k.A.
collyre en solution: Latanoprostum
Horus Pharma Suisse SA
B
FB
G
Latazed 50 ug/ml
5 ml
PR
PR
k.A.
collyre en solution: Latanoprostum
Horus Pharma Suisse SA
B
FB
G
Latazed 50 ug/ml
3 x 2.5 ml
PR
PR
k.A.
collyre en solution: Latanoprostum
Horus Pharma Suisse SA
B
FB
G
Latazed 50 ug/ml
3 x 5 ml
PR
PR
k.A.
collyre en solution: Latanoprostum
Horus Pharma Suisse SA
B
FB
G
Cymbalta 30 mg
28
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 30 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 30 mg
28
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 30 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
14
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
14
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
28
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
28
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
84
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
Cymbalta 60 mg
84
PR
PR
k.A.
magensaftresistente Hartkapseln: Duloxetinum 60 mg
Pharma Nova GmbH
B
FB
G
show caption
Red = Original
CM
= Co-Marketing
EFP = Ex-Factory-Price, exkl. VAT CHF
Green = Generic Drug
V/S
= vaccine/blood product
CP = Consumer Price, inkl. VAT CHF
Black = not classified
A
= Anesthetic
PR = Price request
Gray background = Pending Permission Extension
SIP
= Short Information for Professionals
SB = Selbstbehalt
H
= Homeopathics
IP
= Information for Professionals
DC = Daily Cost
A
= Anthroposophics
CI
= Consumer Information
SL = Official reimbursement list of Switzerland.
Ph
= Phytotherapeutics
L
= Limitations
SO = Original according to SL
Cas Reg.Nr. = CAS Registry
G
= Google Search by Product Name
SG = Generic according to SL
P
= Import parallel
FB
= Drugs Feedback
LPPA = Liste des produits pharmaceutiques pour application spéciale
Legal Disclaimer
ATC-Browser
|
Drugs A-Z
|
Recent Registrations
2025
©ywesee GmbH
Settings
|
Help
|
FAQ
|
Login
|
Contact
|
Home